NCT07213895View on ClinicalTrials.gov

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

September 15, 2025

Study Completion Date

September 18, 2025

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Empagliflozin/Linagliptin/Metformin HCL

One Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg extended release film-coated tablet

DRUG

Trijardy® XR Extended release film coated tablets

One Trijardy® 25mg/5mg/1000mg Extended Release Tablets

Trial Locations (1)

925161

ACDIMA Center, Amman

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT07213895 - Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets | Biotech Hunter | Biotech Hunter